JP2023548945A5 - - Google Patents
Info
- Publication number
- JP2023548945A5 JP2023548945A5 JP2023528750A JP2023528750A JP2023548945A5 JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5 JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/129067 | 2020-11-16 | ||
| PCT/CN2020/129067 WO2022099695A1 (en) | 2020-11-16 | 2020-11-16 | Cd164 fusion and uses thereof |
| PCT/CN2021/129378 WO2022100555A1 (en) | 2020-11-16 | 2021-11-08 | Cd164 fusion and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548945A JP2023548945A (ja) | 2023-11-21 |
| JP2023548945A5 true JP2023548945A5 (enExample) | 2024-09-19 |
Family
ID=81600756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528750A Pending JP2023548945A (ja) | 2020-11-16 | 2021-11-08 | Ｃｄ１６４融合タンパク質およびその適用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240002469A1 (enExample) |
| EP (1) | EP4244260A4 (enExample) |
| JP (1) | JP2023548945A (enExample) |
| CN (4) | CN115947871A (enExample) |
| WO (2) | WO2022099695A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022099695A1 (en) * | 2020-11-16 | 2022-05-19 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Cd164 fusion and uses thereof |
| CN116609531B (zh) * | 2023-05-23 | 2025-10-31 | 哈尔滨医科大学 | Mydgf在治疗血管内模增生的制药和医疗器械中的应用 |
| WO2025047991A1 (en) * | 2023-09-01 | 2025-03-06 | Boehringer Ingelheim International Gmbh | Myeloid-derived growth factor for use in treating or preventing a liver disorder |
| CN119798458B (zh) * | 2024-12-05 | 2025-09-26 | 河南大学 | 一种dr5和mydgf的融合蛋白及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045074A1 (es) * | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| AU2006207471A1 (en) * | 2005-01-24 | 2006-07-27 | Laboratoires Serona S.A. | Use of soluble CD164 variants in inflammatory and/or autoimmune disorders |
| DK2859015T3 (en) * | 2012-06-08 | 2018-06-18 | Alkermes Inc | LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS |
| AU2013371826A1 (en) * | 2013-01-01 | 2015-08-13 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| EP3157558A2 (en) * | 2014-06-23 | 2017-04-26 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of peanut allergies |
| BR112017008157A2 (pt) * | 2014-10-24 | 2017-12-19 | Bristol Myers Squibb Co | polipeptídeos de fgf-21 modificados e usos dos mesmos |
| US11203629B2 (en) * | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
| CN111544572B (zh) * | 2020-05-15 | 2022-06-07 | 中山大学 | Mydgf蛋白在制备端粒酶表达和细胞衰老调控剂中的应用 |
| WO2022099695A1 (en) * | 2020-11-16 | 2022-05-19 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Cd164 fusion and uses thereof |
-
2020
- 2020-11-16 WO PCT/CN2020/129067 patent/WO2022099695A1/en not_active Ceased
-
2021
- 2021-11-08 EP EP21891080.0A patent/EP4244260A4/en active Pending
- 2021-11-08 CN CN202211627764.4A patent/CN115947871A/zh active Pending
- 2021-11-08 CN CN202310893591.9A patent/CN117843806A/zh active Pending
- 2021-11-08 CN CN202211627725.4A patent/CN116003634A/zh active Pending
- 2021-11-08 CN CN202180009089.6A patent/CN115003702B/zh active Active
- 2021-11-08 JP JP2023528750A patent/JP2023548945A/ja active Pending
- 2021-11-08 WO PCT/CN2021/129378 patent/WO2022100555A1/en not_active Ceased
- 2021-11-08 US US18/037,257 patent/US20240002469A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102927838B1 (ko) | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 | |
| US11858975B2 (en) | Multi-domain active protein for treating metabolic diseases | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP5373855B2 (ja) | 選択可能な特性を有するハイブリッドポリペプチド | |
| JP2025114622A (ja) | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 | |
| CN105008395B (zh) | 长效单链胰岛素类似物 | |
| CN109310641A (zh) | 用于受控和持续释放的elp融合蛋白 | |
| KR20170049319A (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| CN103370083A (zh) | 具有增强的作用持续时间的工程化多肽 | |
| CA3151351A1 (en) | Compositions and particles for payload delivery | |
| US10815286B2 (en) | Fusion protein for treating intestinal diseases | |
| CN115003702A (zh) | Cd164融合蛋白及其应用 | |
| WO2023280133A1 (zh) | 融合蛋白及其应用 | |
| CN118076373A (zh) | 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物 | |
| CN111234015B (zh) | 用于延长药物半衰期的抗体、其融合蛋白和应用 | |
| JP2023509189A5 (enExample) | ||
| RU2795548C2 (ru) | Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки | |
| HK40091844A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| JPWO2009005000A1 (ja) | ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法 | |
| HK40086042A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| HK40012348B (zh) | 用於预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物 | |
| RU2023111124A (ru) | Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки | |
| HK40012348A (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |